Company intelligence / Profile preview

CancerFree Biotech

Taipei, Taiwanx.com ↗

Ownership: Private
Development stage: Commercial

Overview

CancerFree Biotech has developed the E.V.A. platform, which creates personalized "tumor avatars" from a patient's blood sample by culturing circulating tumor cells into three-dimensional organoids. These avatars are used to test various anti-cancer drugs ex vivo, helping oncologists select the most effective treatment for individual patients while reducing unnecessary side effects and ineffective therapies. The company also offers its technology as a B2B service to pharmaceutical companies for drug screening on real patient-derived models.

Therapeutic areas: Oncology
Modalities: Organoid culture systems (patient-derived tumor organoids)Ex vivo drug testing platformsAI image recognition for cell analysisCell therapy and cancer vaccine research applications
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on CancerFree Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CancerFree Biotech.

Explore the full profile